Publications by authors named "Thomas Langbein"

Claim this Profile
T
The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy.
Aviral Singh, Sebastian Sanduleanu, Harshad R Kulkarni, Thomas Langbein, Philippe Lambin

Front Endocrinol (Lausanne)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of fasting prior to F-rhPSMA-7.3 (Flotufolastat F-18) PET/CT on biodistribution and tumor uptake.
Sonia Grigorascu, Thomas Langbein, Isabel Rauscher, Calogero D'Alessandria, Tobias Maurer

EJNMMI Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Analysis of Morphological and Functional Effects of Ac- and Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands.
Benedikt Feuerecker, Andrei Gafita, Thomas Langbein, Robert Tauber, Christof Seidl

Int J Mol Sci· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of [Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years.
Robert Tauber, Karina Knorr, Margitta Retz, Isabel Rauscher, Sonia Grigorascu, Thomas Langbein

J Nucl Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Role of Ga-PSMA11 PET-Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy.
Lukas Lunger, Maythinee Chantadisai, Amir Karimzadeh, Isabel Rauscher, Calogero D'Alessandria, Thomas Langbein

J Nucl Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology.
Thomas Langbein, Hui Wang, Isabel Rauscher, Markus Kroenke, Karina Knorr

J Nucl Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study.
Harun Ilhan, Markus Kroenke, Alexander Wurzer, Marcus Unterrainer, Matthias Heck, Thomas Langbein

J Nucl Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with Lu-PSMA and Combined Ac- and Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation.
Thomas Langbein, Harshad R Kulkarni, Christiane Schuchardt, Dirk Mueller, Gerd Fabian Volk

Diagnostics (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Influence of Specific Activity on the Biodistribution of F-rhPSMA-7.3: A Retrospective Analysis of Clinical PET Data.
Thomas Langbein, Alexander Wurzer, Andrei Gafita, Andrew Robertson, Hui Wang

J Nucl Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole-body uptake classification and prostate cancer staging in Ga-PSMA-11 PET/CT using dual-tracer learning.
Nicolò Capobianco, Ludovic Sibille, Maythinee Chantadisai, Andrei Gafita, Thomas Langbein

Eur J Nucl Med Mol Imaging· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of High-Dose Botulinum Toxin Injections for Parotid and Submandibular Gland Radioprotection.
Joerg Mueller, Thomas Langbein, Aditi Mishra, Richard P Baum

Toxins (Basel)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Positron emission tomography with computed tomography/magnetic resonance imaging for primary staging of prostate cancer].
Ergela Hasa, Thomas Langbein, Matthias Eiber, Karina Knorr

Radiologe· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities for Multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations.
Paul Lingor, Jan C Koch, Jeffrey M Statland, Sumaira Hussain, Christiane Hennecke, Thomas Langbein

Amyotroph Lateral Scler Frontotemporal Degener· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy.
Hui Wang, Thomas Amiel, Christoph Würnschimmel, Thomas Langbein, Katja Steiger

EJNMMI Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positive Predictive Value and Correct Detection Rate of F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard.
Maythinee Chantadisai, Gabriel Buschner, Markus Krönke, Isabel Rauscher, Thomas Langbein

J Nucl Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A rare case of polyostotic fibrous dysplasia detected on F-rhPSMA-7 PET/CT.
Hui Wang, Matthias Eiber, Thomas Langbein

Eur J Nucl Med Mol Imaging· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidental Finding of Colon Carcinoma Related to High Uptake in 18F-PSMA-1007 PET.
Ayça Arçay, Matthias Eiber, Thomas Langbein

Clin Nucl Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.
Matthias Eiber, Markus Kroenke, Alexander Wurzer, Lena Ulbrich, Lena Jooß, Thomas Langbein

J Nucl Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, F-rhPSMA-7, in Patients with Prostate Cancer.
So Won Oh, Alexander Wurzer, Eugene J Teoh, Sohee Oh, Thomas Langbein

J Nucl Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney.
Jingjing Zhang, Harshad R Kulkarni, Aviral Singh, Christiane Schuchardt, Karin Niepsch, Thomas Langbein

J Nucl Med· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Thomas Langbein, Wolfgang A Weber, Matthias Eiber

J Nucl Med· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Detoxsan powder on diarrhea caused by gastrointestinal neuroendocrine tumors.
Thomas Langbein, Wilfried Dathe, Anika Deuerling, Richard P Baum

World J Gastroenterol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
Harshad R Kulkarni, Aviral Singh, Thomas Langbein, Christiane Schuchardt, Dirk Mueller

Br J Radiol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies.
Thomas Langbein, Guillaume Chaussé, Richard P Baum

J Nucl Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept.
Richard P Baum, Thomas Langbein, Aviral Singh, Mostafa Shahinfar, Christiane Schuchardt

Nucl Med Mol Imaging· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis